MarketWatch - Top Stories

MarketWatch, a leading publisher of business and financial news, offers users up-to-the minute news, investment tools, and subscription products.
  1. The company only included a percentage of patients in the trial in a Thursday data release.
  2. Investors were hoping for accelerated approval so the drug could quickly begin bringing in revenue. But the new trial results also undermine the core reasons AbbVie bought Stemcentrx and Rova-T in the first place.
  3. Headlines validate thesis of Aaron Sorkin’s film about Mark Zuckerberg.
  4. Oil prices retreat from a seven-week high Thursday, pressured by ongoing gains in U.S. production, as the risk of a global trade war weighed on the stock market.
  5. Micron Technology Inc. investors should expect to be surprised when the company reports earnings, as the options market is preparing for a bigger-than-average post-results reaction in the stock.
  6. The contestants on the reality competition’s 10th season shared their approaches to saving, investing and running a small business.
  7. The Bank of England leaves interest rates unchanged at 0.5% on Thursday, but delivers a policy statement hawkish enough to build expectations for future rate increases. Brace for moves in May and November, says Rabobank market economist Stefan Koopman.
  8. Demand for fur in the U.S. has actually increased.
  9. Danielle Town’s 5 Buffett-inspired investment lessons.
  10. Gold futures climb on Thursday to settle at their highest in more than two weeks, extending their gain from a day earlier as the precious metal tracked a dollar limited by signs the Federal Reserve will stick to a more-conservative script with interest-rate policy this year.